Gastrointestinal Cancer
Conditions
Keywords
Esophageal cancer, Gastric cancer, Colorectal cancer
Brief summary
In this study, researchers wanted to learn more about the effect of Aspirin taken as low dose (75 - 300 mg) in preventing stomach, colorectal and esophagus cancer. The researchers were interested in the effect by duration of aspirin use and the effect on the time since aspirin intake has been stopped in preventing stomach, colorectal and esophagus cancer. In addition, the study also looked into the time patients survived after being diagnosed (survival rate) with cancer and number of cancer patients who died (case fatality rate). The study was based on an electronic database managed by the Health Authority in Hong Kong containing anonymized clinical information of patients living in Hong Kong.
Interventions
Follow clinical administration
Sponsors
Bayer
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
40 Years to No maximum
Healthy volunteers
No
Inclusion criteria
\- Received prescription of either low-dose aspirin (75-300 mg) or paracetamol monotherapy during enrolment period.
Exclusion criteria
* Received prescription of aspirin monotherapy or combination one year prior to the index date * Recorded diagnoses of any type of cancer before the index date * Recorded procedures of colectomy, gastrectomy prior to the index date * Age \< 40 years
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Incidence rate ratio of colorectal cancer among users of low-dose-aspirin (exposed) and users of paracetamol monotherapy (non-exposed) | Retrospective analysis between 1st January 2004 and 31st December 2008 | Ratio of incidence (per 10,000 person years) among users of low-dose-aspirin (exposed) and users of paracetamol monotherapy (non-exposed) |
| Incidence rate ratio of gastric cancer among users of low-dose-aspirin (exposed) and users of paracetamol monotherapy (non-exposed) | Retrospective analysis between 1st January 2004 and 31st December 2008 | Ratio of incidence (per 10,000 person years) among users of low-dose-aspirin (exposed) and users of paracetamol monotherapy (non-exposed) |
| Incidence rate ratio of esophageal cancer among users of low-dose-aspirin (exposed) and users of paracetamol monotherapy (non-exposed) | Retrospective analysis between 1st January 2004 and 31st December 2008 | Ratio of incidence (per 10,000 person years) among users of low-dose-aspirin (exposed) and users of paracetamol monotherapy (non-exposed) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Case-fatality and survival rate | Retrospective analysis between 1st January 2004 and 31st December 2008 | For colorectal cancer, gastric or oesophageal |
| Duration of aspirin use | Retrospective analysis between 1st January 2004 and 31st December 2008 | Minimum duration of aspirin use to confer the protective effects in preventing colorectal, gastric and esophageal cancer |
| Risk of colorectal, gastric and esophageal cancer after discontinuation of aspirin use | Retrospective analysis between 1st January 2004 and 31st December 2008 | Logistic regression will be conducted based on nested case-control study with stratification on the recency of exposure with current use, past use, and distant use of aspirin. |
Countries
Hong Kong
Outcome results
None listed